Experimed

GÖNDERBİLGİ
EnglishTürkçe

Araştırma Makalesi


DOI :10.26650/experimed.2019.19024   IUP :10.26650/experimed.2019.19024    Tam Metin (PDF)

Sol Ventrikül Hipertrofisinde (RRM1, RRM2, ERCC2) DNA Tamir Gen Polimorfizmleri

Fatma Tuba Akdeniz, Seda Güleç Yılmaz, Cemil Selim İsbir, Yaşar Birkan, David Sinan Esensoy, Gözde Özcan, Atike Tekeli Kunt, Turgay İsbir

Amaç: Sol Ventrikül Hipertrofisi (SVH) kardiak hastalıklar için sık görülen bir risk faktörüdür. Bu çalışmada DNA tamir gen polimorfizimleri ve sol ventrikül hipertrofisi arasındaki ilişkiyi araştırdık.


Gereç ve Yöntem: Periferik kandan izole edilen DNA örnekleri RRM1 (rs12806698), RRM2 (rs6859180) ve ERCC2 (rs13181) genleri için Gerçek Zamanlı Polimeraz Zincir reaksiyon (GZ- PZR) ile genotiplendirildi.


Bulgular: Kontrol ve hasta grupları arasında RRM2 (p=0,365) ve ERCC2 (p=0,740) genleri için önemli fark olmamasına rağmen, RRM1 (A>C) CC genotip frekansı SVH hastalarında kontrol grubuna göre anlamlı şekilde yüksek olarak bulundu (p=0,018). RRM1 geni yabani tip A allel taşıyıcıları sağlıklı kontrolde SVH li hastalara göre anlamlı şekilde yüksek olarak tespit edildi (p=0,029).


Sonuç: RRM1 CC genotipi SVH’ne karşı bir risk faktörü olabilirken RRM1 AC genotipi ve A alleli koruyucu role sahip olabilir.

Anahtar Kelimeler: SVH, DNA tamir genleri, polimorfizm
DOI :10.26650/experimed.2019.19024   IUP :10.26650/experimed.2019.19024    Tam Metin (PDF)

Preliminary Study: DNA Repair Gene Polymorphisms (RRM1, RRM2, ERCC2) In Left Ventricular Hypertrophy

Fatma Tuba Akdeniz, Seda Güleç Yılmaz, Cemil Selim İsbir, Yaşar Birkan, David Sinan Esensoy, Gözde Özcan, Atike Tekeli Kunt, Turgay İsbir

Objective: Left ventricular hypertrophy (LVH) accounts for one of the most important independent risk factors for cardiac diseases. In the present study, we investigate the relationship of DNA repair gene polymorphisms and LVH.


Material and Method: DNA samples isolated from peripheral blood were genotyped with real-time polymerase chain reaction (RT-PCR) for RRM1 (rs12806698), RRM2 (rs6859180) and ERCC2 (rs13181) genes.


Results: Although there were no significant differences for RRM2 (p=0.365) and ERCC2 (p=0.740) genes. RRM1 (A>C) CC genotype was significantly higher in the LVH than control groups (p=0.018). RRM1gene wild type A allele carriers were significantly higher in the healthy controls than the LVH group (p=0.029).


Conclusion: RRM1 gene CC genotype could be a risk factor, whereas the RRM1 gene AC genotype and the A allele might play a protective role against LVH.

Anahtar Kelimeler: LVH, DNA repair genes, polymorphism

PDF Görünüm

Referanslar

  • 1. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation 2017; 135: 146-603. [CrossRef] google scholar
  • 2. Messerli FH, Schmieder R. Left ventricular hypertrophy. A cardiovascular risk factor in essential hypertension. Drugs 1986; 31: 192-201. [CrossRef] google scholar
  • 3. Davidson, BP, Giraud GD. Left ventricular function and the systemic arterial vasculature: remembering what we have learned. J Am Soc Echocardiogr 2012; 25: 891-94. [CrossRef] google scholar
  • 4. Pokharel P, Bella JN. Regression of left ventricular hypertrophy: Lessons from clinical trials. OA Evidence-Based Medicine 2013; 1: 13. https://doi.org/10.13172/2053-2636-1-2-1110. [CrossRef] google scholar
  • 5. Elledge SJ, Zhou Z, Allen JB. Ribonucleotide reductase: regulation, regulation, regulation. Trends Biochem Sci 1992; 17: 119-23. [CrossRef] google scholar
  • 6. Oh IJ, Ban HJ, Kim KS, Song SY, Na KJ, Kim YH, et al. Response to gemcitabine-platinum chemotherapy by single nucleotide polymorphisms of RRM1 and ERCC1 genes in patients with non-small-cell lung cancer. Thorac Cancer 2012; 3: 19-26. [CrossRef] google scholar
  • 7. Thomson KS, Odom GL, Murry CE, Mahairas GG, Moussavi-Harami F, Teichman SL, et al. Translation of Cardiac Myosin Activation with 2-deoxy-ATP to Treat Heart Failure via an Experimental Ribonucleotide Reductase-Based Gene Therapy. JACC Basic Transl Sci 2016; 1: 666-79. [CrossRef] google scholar
  • 8. Korte FS, Dai J, Buckley K, Feest ER, AdamekN, Geeves MA, et al. Upregulation of cardiomyocyte ribonucleotide reductase increases intracellular 2 deoxy-ATP, contractility, and relaxation. J Mol Cell Cardiol 2011; 51: 894-901. [CrossRef] google scholar
  • 9. Nowakowski SG, Kolwicz SC, Korte FS, Luo Z, Robinson-Hamm JN, Page JL, et al. Transgenic overexpression of ribonucleotide reductase improves cardiac performance. Proc Natl Acad Sci U S A 2013; 110: 6187-92. [CrossRef] google scholar
  • 10. Kadota S, Carey J, Reinecke H, Leggett J, Teichman S, Laflamme MA, et al. Ribonucleotide reductase-mediated increase in dATP improves cardiac performance via myosin activation in a large animal model of heart failure. Eur J Heart Fail 2015; 17: 772-81. [CrossRef] google scholar
  • 11. Cervelli T, Borghini A, Galli A, Andreassi MG. DNA damage and repair in atherosclerosis: current insights and future perspectives. Int J Mol Sci 2012; 13:16929-44. [CrossRef] google scholar
  • 12. Gallaugher LD, Henry JC, Kearns PN, Elford HL, Bergdall VK, Cardaunel AJ. Ribonucleotide reductase inhibitors reduce atherosclerosis in a double-injury rabbit model. Comp Med 2009; 59: 567-72. google scholar
  • 13. Nowsheen S, Yang ES. The Intersection Between Dna Damage Response And Cell Death Pathways. Exp Oncol 2012; 34: 243-54. google scholar
  • 14. Choi YH, Cowan DB, Moran AM, Colan SD, Stamm C, Takeuchi K, et al. Myocyte apoptosis occurs early during the development of pressure-overload hypertrophy in infant myocardium. J Thorac Cardiovasc Surg 2009; 137: 1356-62. [CrossRef] google scholar
  • 15. Bepler G, Zheng Z, Gautam A, Sharma S, Cantor A, Sharma A, et al. Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer 2005; 47: 183-92. [CrossRef] google scholar
  • 16. Garavaglia GE, Messerli FH, Schmieder RE, Nunez BD, Oren S. Sex differences in cardiac adaptation to essential hypertension. Eur Heart J 1989; 10: 1110-4. [CrossRef] google scholar
  • 17. Gradman AH, Alfayoumi F. From Left Ventricular Hypertrophy to Congestive Heart Failure: Management of Hypertensive Heart Disease. Prog Cardiovasc Dis 2006; 48: 326-34. [CrossRef] google scholar

Atıflar

Biçimlendirilmiş bir atıfı kopyalayıp yapıştırın veya seçtiğiniz biçimde dışa aktarmak için seçeneklerden birini kullanın


DIŞA AKTAR



APA

Akdeniz, F., Güleç Yılmaz, S., İsbir, C., Birkan, Y., Esensoy, D., Özcan, G., Tekeli Kunt, A., & İsbir, T. (0001). Sol Ventrikül Hipertrofisinde (RRM1, RRM2, ERCC2) DNA Tamir Gen Polimorfizmleri. Experimed, 9(3), 99-104. https://doi.org/10.26650/experimed.2019.19024


AMA

Akdeniz F, Güleç Yılmaz S, İsbir C, Birkan Y, Esensoy D, Özcan G, Tekeli Kunt A, İsbir T. Sol Ventrikül Hipertrofisinde (RRM1, RRM2, ERCC2) DNA Tamir Gen Polimorfizmleri. Experimed. 0001;9(3):99-104. https://doi.org/10.26650/experimed.2019.19024


ABNT

Akdeniz, F.; Güleç Yılmaz, S.; İsbir, C.; Birkan, Y.; Esensoy, D.; Özcan, G.; Tekeli Kunt, A.; İsbir, T. Sol Ventrikül Hipertrofisinde (RRM1, RRM2, ERCC2) DNA Tamir Gen Polimorfizmleri. Experimed, [Publisher Location], v. 9, n. 3, p. 99-104, 0001.


Chicago: Author-Date Style

Akdeniz, Fatma Tuba, and Seda Güleç Yılmaz and Cemil Selim İsbir and Yaşar Birkan and David Sinan Esensoy and Gözde Özcan and Atike Tekeli Kunt and Turgay İsbir. 0001. “Sol Ventrikül Hipertrofisinde (RRM1, RRM2, ERCC2) DNA Tamir Gen Polimorfizmleri.” Experimed 9, no. 3: 99-104. https://doi.org/10.26650/experimed.2019.19024


Chicago: Humanities Style

Akdeniz, Fatma Tuba, and Seda Güleç Yılmaz and Cemil Selim İsbir and Yaşar Birkan and David Sinan Esensoy and Gözde Özcan and Atike Tekeli Kunt and Turgay İsbir. “Sol Ventrikül Hipertrofisinde (RRM1, RRM2, ERCC2) DNA Tamir Gen Polimorfizmleri.” Experimed 9, no. 3 (Dec. 2024): 99-104. https://doi.org/10.26650/experimed.2019.19024


Harvard: Australian Style

Akdeniz, F & Güleç Yılmaz, S & İsbir, C & Birkan, Y & Esensoy, D & Özcan, G & Tekeli Kunt, A & İsbir, T 0001, 'Sol Ventrikül Hipertrofisinde (RRM1, RRM2, ERCC2) DNA Tamir Gen Polimorfizmleri', Experimed, vol. 9, no. 3, pp. 99-104, viewed 22 Dec. 2024, https://doi.org/10.26650/experimed.2019.19024


Harvard: Author-Date Style

Akdeniz, F. and Güleç Yılmaz, S. and İsbir, C. and Birkan, Y. and Esensoy, D. and Özcan, G. and Tekeli Kunt, A. and İsbir, T. (0001) ‘Sol Ventrikül Hipertrofisinde (RRM1, RRM2, ERCC2) DNA Tamir Gen Polimorfizmleri’, Experimed, 9(3), pp. 99-104. https://doi.org/10.26650/experimed.2019.19024 (22 Dec. 2024).


MLA

Akdeniz, Fatma Tuba, and Seda Güleç Yılmaz and Cemil Selim İsbir and Yaşar Birkan and David Sinan Esensoy and Gözde Özcan and Atike Tekeli Kunt and Turgay İsbir. “Sol Ventrikül Hipertrofisinde (RRM1, RRM2, ERCC2) DNA Tamir Gen Polimorfizmleri.” Experimed, vol. 9, no. 3, 0001, pp. 99-104. [Database Container], https://doi.org/10.26650/experimed.2019.19024


Vancouver

Akdeniz F, Güleç Yılmaz S, İsbir C, Birkan Y, Esensoy D, Özcan G, Tekeli Kunt A, İsbir T. Sol Ventrikül Hipertrofisinde (RRM1, RRM2, ERCC2) DNA Tamir Gen Polimorfizmleri. Experimed [Internet]. 22 Dec. 2024 [cited 22 Dec. 2024];9(3):99-104. Available from: https://doi.org/10.26650/experimed.2019.19024 doi: 10.26650/experimed.2019.19024


ISNAD

Akdeniz, Fatma Tuba - Güleç Yılmaz, Seda - İsbir, Cemil Selim - Birkan, Yaşar - Esensoy, David Sinan - Özcan, Gözde - Tekeli Kunt, Atike - İsbir, Turgay. “Sol Ventrikül Hipertrofisinde (RRM1, RRM2, ERCC2) DNA Tamir Gen Polimorfizmleri”. Experimed 9/3 (Dec. 2024): 99-104. https://doi.org/10.26650/experimed.2019.19024



ZAMAN ÇİZELGESİ


Kabul14.11.2019

LİSANS


Attribution-NonCommercial (CC BY-NC)

This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.


PAYLAŞ




İstanbul Üniversitesi Yayınları, uluslararası yayıncılık standartları ve etiğine uygun olarak, yüksek kalitede bilimsel dergi ve kitapların yayınlanmasıyla giderek artan bilimsel bilginin yayılmasına katkıda bulunmayı amaçlamaktadır. İstanbul Üniversitesi Yayınları açık erişimli, ticari olmayan, bilimsel yayıncılığı takip etmektedir.